国家科技部中国科技论文统计源期刊   中国科技核心期刊   WHO西太平洋地区医学索引(WPRIM)收录期刊   湖北优秀期刊
《药物流行病学杂志》官方网站与投审稿系统变更通知<点击查看详情>
曲普瑞林在子宫内膜异位症术后的临床应用
Clinical observation on the effects of Triptorelin treatment for postoperative patients with pelvic endometriosis
  
DOI:
中文关键词:  曲普瑞林 子宫内膜异位症 手术,保守性
英文关键词:Triptorelin,pelvic endometriosis,conservative operation
基金项目:
谭红
湖北省中山医院 武汉430033
摘要点击次数: 1749
全文下载次数: 131
中文摘要:
      目的:探讨促性腺激素释放激素激动药曲普瑞林用于子宫内膜异位症保守性手术后辅助治疗的疗效和安全性。方法:回顾分析37例子宫内膜异位症患者保守性手术后的随访资料,比较应用曲普瑞林与未用药组的复发率。观察药物不良反应。结果:观察组复发率5.5%,明显低于对照组复发率(36.8%),P<0.05。曲普瑞林不良反应主要为低雌激素引起的绝经期症状,停药后不良反应消失,不影响疗程,停药后4~9周月经恢复。结论:曲普瑞林用于子宫内膜异位症的术后辅助治疗是有效和安全的。
英文摘要:
      Objective: To investigate the effects and safety of Triptorelin for treating patients with pelvic endometriosis after conservative operation.Method: 37 Postoperative pelvic endometriosis cases were analyzed retrospectively. Of these cases, 18 were administered Triptorelin (study group), other 19 cases hadn't taken any hormone drugs(control group). Recurrence rate was compared between two group, and the main side effects were recorded respectively.Result: The recurrence rate of study group was )5.5%), which was significantly lower than that of control group()36.8%)), P<)0.05). Hypoestrogenic effects occurred to study group who received Triptorelin, which can be alleviate after treatment.Menstruation recovered in all patients in 4-9 weeks after treatment.Conclusion: The treatment of Triptorelin on postoperative patients with pelvic endometriosis is effective and safe.
查看全文  查看/发表评论  下载PDF阅读器
关闭